/
EDSA
$7.67-$0.52 (-6.35%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$78.8M
10M shares
52-week range
$0.72 – $20.32
35% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-29.57
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $211.8K | $410.9K | $328.8K | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $445.3K | $101.3K | $17.6K | $118.8K | $118.2K | $183.5K | $186.0K | $119.3K |
| Gross profit | −$233.5K | $309.6K | $311.2K | −$118.8K | −$118.2K | −$183.5K | −$186.0K | −$119.3K |
| Gross margin | -110.2% | 75.3% | 94.6% | — | — | — | — | — |
| R&D | $2.1M | $1.1M | $3.3M | $17.9M | $13.3M | $4.8M | $2.9M | $3.7M |
| Operating income | −$5.1M | −$2.8M | −$6.4M | −$23.7M | −$18.4M | −$9.2M | −$7.0M | −$7.9M |
| EBITDA | −$4.8M | −$2.8M | −$6.3M | −$13.2M | −$17.4M | −$8.2M | −$6.0M | −$7.1M |
| Net income | −$5.0M | −$2.7M | −$6.4M | −$13.3M | −$17.5M | −$8.4M | −$6.2M | −$7.2M |
| Net margin | -2378.6% | -662.3% | -1935.6% | — | — | — | — | — |
| EPS (diluted) | -10.54 | -4.15 | -5.18 | -7.73 | -8.37 | -2.93 | -1.93 | -1.27 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.94 | $-1.94–$-1.94 | 1 |
| 2027 | $19M | $-1.96 | $-1.96–$-1.96 | 1 |
| 2028 | $49M | $-0.93 | $-1.28–$-0.58 | 2 |
| 2029 | $10M | $-2.04 | $-2.04–$-2.04 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.00
Price
$7.67
Implied downside
-74%
Peer comparison
Edesa Biotech, Inc. Common Shares
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
www.edesabiotech.com- Employees
- 17
- IPO / List date
- Jun 9, 2010
- HQ
- MARKHAM
Held by traders on TradeandTell
No one on the platform currently holds EDSA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 25,000 | $61.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-10-11 | 1-for-7reverse |
| 2018-05-07 | 1-for-7reverse |
Recent trades on TradeandTell
No one on the platform has traded EDSA yet.
